NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $4.28 -0.04 (-0.81%) As of 09:40 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About TriSalus Life Sciences Stock (NASDAQ:TLSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TriSalus Life Sciences alerts:Sign Up Key Stats Today's Range$4.21▼$4.2150-Day Range$4.15▼$5.7452-Week Range$2.20▼$7.95Volume1,054 shsAverage Volume307,383 shsMarket Capitalization$263.87 millionP/E RatioN/ADividend YieldN/APrice Target$10.20Consensus RatingHold Company Overview TriSalus Life Sciences, Inc. is an oncology-focused life sciences company developing medical technologies and therapies for patients with difficult-to-treat liver and pancreatic tumors. The company’s approach is designed to address the unique biological and physical barriers that can limit the delivery of cancer treatments to solid tumors. TriSalus’ principal technology is its Pressure-Enabled Drug Delivery (PEDD) platform, which is intended to improve the distribution of therapeutic agents within tumors through regional infusion. The company’s TriNav Infusion System is used to support targeted delivery procedures, including treatments involving the liver and pancreas. TriSalus also develops investigational immuno-oncology therapies intended for use with its delivery platform and other cancer treatments. The company’s clinical and commercial activities focus primarily on oncology applications in the United States, particularly hepatocellular carcinoma, intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. TriSalus has expanded its capabilities through the development and acquisition of drug-delivery and immunotherapy technologies. The company is led by Chief Executive Officer Steve Damon.AI Generated. May Contain Errors. Read More TriSalus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreTLSI MarketRank™: TriSalus Life Sciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 469th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingTriSalus Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTriSalus Life Sciences has a consensus price target of $10.20, representing about 136.1% upside from its current price of $4.32.Amount of Analyst CoverageTriSalus Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about TriSalus Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TriSalus Life Sciences are expected to grow in the coming year, from ($0.53) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TriSalus Life Sciences is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TriSalus Life Sciences is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about TriSalus Life Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.49% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 28.81, which indicates bearish sentiment.Change versus previous monthShort interest in TriSalus Life Sciences has recently decreased by 9.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.50 News SentimentTriSalus Life Sciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for TriSalus Life Sciences this week, compared to 3 articles on an average week.Search Interest1 people have searched for TLSI on MarketBeat in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLSI Stock News HeadlinesTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock Has Average Target Price of $10.20 According to AnalystsOctober 4 at 4:15 AM | americanbankingnews.comH.C. Wainwright Keeps Their Buy Rating on TriSalus Life Sciences (TLSI)October 3 at 8:59 AM | theglobeandmail.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 5 at 1:00 AM | Banyan Hill Publishing (Ad)QT Imaging (NASDAQ:QTI) versus TriSalus Life Sciences (NASDAQ:TLSI) Head to Head AnalysisSeptember 30, 2026 | americanbankingnews.comTLSI Stock Gets Reduced EPS Estimate from HC WainwrightSeptember 27, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Faeth Therapeutics (FTH), TriSalus Life Sciences (TLSI) and Immuneering (IMRX)September 24, 2026 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: TriSalus Life Sciences (TLSI) and Eli Lilly & Co (LLY)September 24, 2026 | theglobeandmail.comTriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav AdvanceSeptember 24, 2026 | marketscreener.comMSee More Headlines TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $6.98 at the start of the year. Since then, TLSI shares have decreased by 38.1% and is now trading at $4.32. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.01. The business had revenue of $11.41 million for the quarter, compared to analyst estimates of $10.27 million. Read the conference call transcript. How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TriSalus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB). Company Calendar Last Earnings8/06/2026Today10/05/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TLSI's financial health is in the Green zone, according to TradeSmith. TLSI has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees102Year Founded2009Price Target and Rating Average Price Target for TriSalus Life Sciences$10.20 High Price Target$12.00 Low Price Target$7.00 Potential Upside/Downside+138.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.23 million Net Margins-62.59% Pretax Margin-62.56% Return on EquityN/A Return on Assets-64.47% Debt Debt-to-Equity Ratio5.05 Current Ratio5.35 Quick Ratio4.97 Sales & Book Value Annual Sales$45.15 million Price / Sales5.84 Cash FlowN/A Price / Cash FlowN/A Book Value($0.68) per share Price / Book-6.30Miscellaneous Outstanding Shares61,580,000Free Float51,538,000Market Cap$263.87 million OptionableNot Optionable Beta0.47 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:TLSI) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
